Dr Niall Tebbutt

Honorary Associate
Medicine, Sydney Medical School
NHMRC Clinical Trials Centre

Telephone +61 3 94971375

Map

Selected grants

2008

  • Preop chemoradiotherapy&postop chemo with capeciabine&oxaliplatin vs capecitabine alone in locally a; Price T, Harvey J, Tebbutt N, Hruby G, Bydder S, Simes R, Zalcberg J; Cancer Australia/Priority Driven Collaborative Cancer Research Scheme.

2005

  • ATTAX2:Phase II of Cetuximab (Erbitux) plus weekly docetaxel chemotherapy in docetaxel refractory patients with EGFR positive advanced oesophago-gastric Cancer.; Tebbutt N, Conley R, Tebbutt N; Alphapharm Pty Ltd/BLO Project.
  • A randomised phase II/III Study to evaluate the role of Mitomycin C, Avastin and Xeloda in patients with metastatic colorectal cancer (The MAX study); Tebbutt N, Kingston D, Conley R; Roche Products Pty Limited/Research Grants.

Selected publications

Download citations: PDF RTF Endnote

Journals

  • Carter, H., Zannino, D., Simes, R., Schofield, D., Howard, K., Zalcberg, J., Price, T., Tebbutt, N. (2014). The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer, 50(3), 535-543. [More Information]
  • Segelov, E., Chan, D., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., Pavlakis, N. (2014). The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. British Journal of Cancer, 111(6), 1122-1131. [More Information]
  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. [More Information]
  • Price, T., Segelov, E., Burge, M., Haller, D., Ackland, S., Tebbutt, N., Karapetis, C., Pavlakis, N., Sobrero, A., Cunningham, D., et al (2013). Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 13(5), 597-611. [More Information]
  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771-774. [More Information]
  • Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Tabernero, J. (2013). Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology / Hematology (online), 85(2), 121-135. [More Information]
  • Price, T., Zannino, D., Wilson, C., Simes, R., Cassidy, J., Van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536. [More Information]
  • Neoptolemos, J., Moore, M., Cox, T., Valle, J., Palmer, D., McDonald, A., Carter, R., Tebbutt, N., Dervenis, C., Smith, D., et al (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308(2), 147-156. [More Information]
  • Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012). Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 6(2), 199-209. [More Information]
  • Deb, S., Ferraro, D., Tebbutt, N., Fox, S. (2011). Australian perspective on the role of targeted therapies in gastroesophageal cancer. Cancer Forum, 35(3), 150-156.
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Chua, A., Shivasami, A., Cummins, M., Weikhardt, A., Tebbutt, N., et al (2011). Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 29(19), 2675-2682. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]
  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis, N., Cunningham, D., Sobrero, A., Haller, D., Shapiro, J. (2010). Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 9(1), 8-14. [More Information]
  • Goldstein, D., Gainford, M., Brown, C., Tebbutt, N., Ackland, S., van Hazel, G., Jefford, M., Abdi, E., Selva-Nayagam, S., Gebski, V., Miller, D., et al (2010). Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology, , 1-7. [More Information]
  • Tebbutt, N., Cummins, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481.
  • Hicks, S., James, R., Wong, N., Tebbutt, N., Wilson, C., Australasian Gastro-Intestinal Trials Group, -. (2009). A case study evaluation of ethics review systems for multicentre clinical trials. Medical Journal of Australia, 191(5), 280-282. [More Information]
  • Mittman, N., Au, H., Tu, D., O'Callaghan, C., Isogai, P., Karapetis, C., Zalcberg, J., Evans, W., Moore, M., Siddiqui, J., Simes, R., Tebbutt, N., et al (2009). Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute, 101(17), 1182-1192. [More Information]
  • Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359(17), 1757-1765. [More Information]
  • Scott, A., Tebbutt, N., Lee, F., Cavicchiolo, T., Liu, Z., Gill, S., Poon, A., Hopkins, W., Smyth, F., Davis, I., et al (2007). A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clinical Cancer Research, 13(11), 3286-3292. [More Information]
  • Jonker, D., O’Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn, M., Price, T., Simes, R., et al (2007). Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine, 357(20), 2040-2048. [More Information]
  • Chong, G., Lee, F., Hopkins, W., Tebbutt, N., Cebon, J., Mountain, A., Chappell, B., Papenfuss, A., Schleyer, P., Davis, I., et al (2005). Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clinical Cancer Research, 11(13), 4818-4826. [More Information]

2014

  • Carter, H., Zannino, D., Simes, R., Schofield, D., Howard, K., Zalcberg, J., Price, T., Tebbutt, N. (2014). The cost effectiveness of bevacizumab when added to capecitabine, with or without mitomycin-C, in first line treatment of metastatic colorectal cancer: Results from the Australasian phase III MAX study. European Journal of Cancer, 50(3), 535-543. [More Information]
  • Segelov, E., Chan, D., Shapiro, J., Price, T., Karapetis, C., Tebbutt, N., Pavlakis, N. (2014). The role of biological therapy in metastatic colorectal cancer after first-line treatment: a meta-analysis of randomised trials. British Journal of Cancer, 111(6), 1122-1131. [More Information]

2013

  • Vickers, M., Karapetis, C., Tu, D., O'Callaghan, C., Price, T., Tebbutt, N., van Hazel, G., Shapiro, J., Pavlakis, N., Gibbs, P., Simes, R., et al (2013). Association of hypomagnesemia with inferior survival in a phase III, randomized study of cetuximab plus best supportive care versus best supportive care alone: NCIC CTG/AGITG CO.17. Annals of Oncology, 24(4), 953-960. [More Information]
  • Price, T., Segelov, E., Burge, M., Haller, D., Ackland, S., Tebbutt, N., Karapetis, C., Pavlakis, N., Sobrero, A., Cunningham, D., et al (2013). Current opinion on optimal treatment for colorectal cancer. Expert Review of Anticancer Therapy, 13(5), 597-611. [More Information]
  • Tebbutt, N., Parry, M., Zannino, D., Strickland, A., van Hazel, G., Pavlakis, N., Ganju, V., Mellor, D., Dobrovic, A., Gebski, V. (2013). Docetaxel plus cetuximab as second-line treatment for docetaxel-refractory oesophagogastric cancer: the AGITG ATTAX2 trial. British Journal of Cancer, 108(4), 771-774. [More Information]
  • Clarke, S., Karapetis, C., Gibbs, P., Pavlakis, N., Desai, J., Michael, M., Tebbutt, N., Price, T., Tabernero, J. (2013). Overview of biomarkers in metastatic colorectal cancer: Tumour, blood and patient-related factors. Critical Reviews in Oncology / Hematology (online), 85(2), 121-135. [More Information]

2012

  • Price, T., Zannino, D., Wilson, C., Simes, R., Cassidy, J., Van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Tebbutt, N. (2012). Bevacizumab is equally effective and no more toxic in elderly patients with advanced colorectal cancer: a subgroup analysis from the AGITG MAX trial: an international randomised controlled trial of Capecitabine, Bevacizumab and Mitomycin C. Annals of Oncology, 23(6), 1531-1536. [More Information]
  • Neoptolemos, J., Moore, M., Cox, T., Valle, J., Palmer, D., McDonald, A., Carter, R., Tebbutt, N., Dervenis, C., Smith, D., et al (2012). Effect of adjuvant chemotherapy with fluorouracil plus folinic acid or gemcitabine vs observation on survival in patients with resected periampullary adenocarcinoma: the ESPAC-3 periampullary cancer randomized trial. JAMA, 308(2), 147-156. [More Information]
  • Price, T., Shapiro, J., Segelov, E., Karapetis, C., Pavlakis, N., Van Cutsem, E., Shah, M., Kang, Y., Tebbutt, N. (2012). Management of advanced gastric cancer. Expert Review of Gastroenterology and Hepatology, 6(2), 199-209. [More Information]

2011

  • Deb, S., Ferraro, D., Tebbutt, N., Fox, S. (2011). Australian perspective on the role of targeted therapies in gastroesophageal cancer. Cancer Forum, 35(3), 150-156.
  • Price, T., Hardingham, J., Lee, C., Townsend, A., Wrin, J., Chua, A., Shivasami, A., Cummins, M., Weikhardt, A., Tebbutt, N., et al (2011). Impact of KRAS and BRAF Gene Mutation Status on Outcomes From the Phase III AGITG MAX Trial of Capecitabine Alone or in Combination With Bevacizumab and Mitomycin in Advanced Colorectal Cancer. Journal of Clinical Oncology, 29(19), 2675-2682. [More Information]
  • Tebbutt, N., Murphy, F., Zannino, D., Wilson, C., Cummins, M., Abdi, E., Strickland, A., Lowenthal, R., Marx, G., Karapetis, C., Shannon, J., Simes, R., et al (2011). Risk of arterial thromboembolic events in patients with advanced colorectal cancer receiving bevacizumab. Annals of Oncology, 22(8), 1834-1838. [More Information]
  • Clarke, S., Yip, S., Brown, C., van Hazel, G., Ransom, D., Goldstein, D., Jeffrey, G., Tebbutt, N., Buck, M., Lowenthal, R., Boland, A., Gebski, V., Simes, R., et al (2011). Single-agent irinotecan or 5-fluorouracil and leucovorin (FOLFIRI) as second-line chemotherapy for advanced colorectal cancer; results of a randomised phase II study (DaVINCI) and meta-analysis. European Journal of Cancer, 47(12), 1826-1836. [More Information]

2010

  • Tebbutt, N., Wilson, K., Gebski, V., Cummins, M., Zannino, D., van Hazel, G., Robinson, B., Broad, A., Ganju, V., Ackland, S., Stockler, M., Simes, R., et al (2010). Capecitabine, Bevacizumab and Mitomycin in First-Line Treatment of Metastatic Colorectal Cancer: Results of the Australasian Gastrointestinal Trials Group Randomized, Phase III MAX Study. Journal of Clinical Oncology, 28(19), 3191-3198. [More Information]
  • Tebbutt, N., Karapetis, C., Segelov, E., Pavlakis, N., Cunningham, D., Sobrero, A., Haller, D., Shapiro, J. (2010). Current Opinion on Optimal Treatment Choices in First-line Therapy for Advanced or Metastatic Colorectal Cancer: Report From the Adelaide Colorectal Tumour Group Meeting; Stockholm, Sweden; September 2008. Clinical Colorectal Cancer, 9(1), 8-14. [More Information]
  • Goldstein, D., Gainford, M., Brown, C., Tebbutt, N., Ackland, S., van Hazel, G., Jefford, M., Abdi, E., Selva-Nayagam, S., Gebski, V., Miller, D., et al (2010). Fixed-dose-rate gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas. Cancer Chemotherapy and Pharmacology, , 1-7. [More Information]
  • Tebbutt, N., Cummins, M., Sourjina, T., Strickland, A., van Hazel, G., Ganju, V., Gibbs, D., Stockler, M., Gebski, V., Zalcberg, J. (2010). Randomised, non-comparative phase II study of weekly docetaxel with cisplatin and 5-fluorouracil or with capecitabine in oesophagogastric cancer: the AGITG ATTAX trial. British Journal of Cancer, 102(3), 475-481.

2009

  • Hicks, S., James, R., Wong, N., Tebbutt, N., Wilson, C., Australasian Gastro-Intestinal Trials Group, -. (2009). A case study evaluation of ethics review systems for multicentre clinical trials. Medical Journal of Australia, 191(5), 280-282. [More Information]
  • Mittman, N., Au, H., Tu, D., O'Callaghan, C., Isogai, P., Karapetis, C., Zalcberg, J., Evans, W., Moore, M., Siddiqui, J., Simes, R., Tebbutt, N., et al (2009). Prospective Cost-Effectiveness Analysis of Cetuximab in Metastatic Colorectal Cancer: Evaluation of National Cancer Institute of Canada Clinical Trials Group CO.17 Trial. Journal of the National Cancer Institute, 101(17), 1182-1192. [More Information]

2008

  • Karapetis, C., Khambata-Ford, S., Jonker, D., O'Callaghan, C., Tu, D., Tebbutt, N., Simes, R., Chalchal, H., Shapiro, J., Robitaille, S., et al (2008). K-ras Mutations and Benefit from Cetuximab in Advanced Colorectal Cancer. New England Journal of Medicine, 359(17), 1757-1765. [More Information]

2007

  • Scott, A., Tebbutt, N., Lee, F., Cavicchiolo, T., Liu, Z., Gill, S., Poon, A., Hopkins, W., Smyth, F., Davis, I., et al (2007). A phase I biodistribution and pharmacokinetic trial of humanized monoclonal antibody Hu3s193 in patients with advanced epithelial cancers that express the Lewis-Y antigen. Clinical Cancer Research, 13(11), 3286-3292. [More Information]
  • Jonker, D., O’Callaghan, C., Karapetis, C., Zalcberg, J., Tu, D., Au, H., Berry, S., Krahn, M., Price, T., Simes, R., et al (2007). Cetuximab for the Treatment of Colorectal Cancer. New England Journal of Medicine, 357(20), 2040-2048. [More Information]

2005

  • Chong, G., Lee, F., Hopkins, W., Tebbutt, N., Cebon, J., Mountain, A., Chappell, B., Papenfuss, A., Schleyer, P., Davis, I., et al (2005). Phase I trial of 131I-huA33 in patients with advanced colorectal carcinoma. Clinical Cancer Research, 11(13), 4818-4826. [More Information]

To update your profile click here. For support on your academic profile contact .